CFF Supporting Phase 1/2 Trial of Phage Therapy for P. aeruginosa Infections

CFF Supporting Phase 1/2 Trial of Phage Therapy for P. aeruginosa Infections

315473

CFF Supporting Phase 1/2 Trial of Phage Therapy for P. aeruginosa Infections

BiomX has been given up to $5 million to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). Trial funding, awarded by the Cystic Fibrosis Foundation (CFF), marks one of several recent studies into phage therapy conducted with foundation support. “Although promising results have been reported in several individual cases, studies like this one will help us evaluate the safety and efficacy of phage as…

You must be logged in to read/download the full post.